Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease.

Area of Science:

• Oncology
• Nanomedicine
• Cancer Biology

Background:

• Advanced endometrial cancer (EC) presents a significant therapeutic challenge due to a lack of effective treatments.
• CXCR4 receptor overexpression is linked to poor prognosis and metastasis in various cancers, highlighting its potential as a therapeutic target.

Purpose of the Study:

• To investigate CXCR4 expression in endometrial cancer patients.
• To develop and validate novel CXCR4-positive (CXCR4+) EC mouse models for therapeutic development.
• To evaluate a CXCR4-targeted nanocarrier for drug delivery in EC.

Main Methods:

• Immunohistochemistry (IHC) was used to assess CXCR4 expression in human EC tissues.
• Orthotopic and subcutaneous EC mouse models were generated using CXCR4-transduced EC cells.
• In vitro and in vivo studies evaluated the efficacy and biodistribution of the T22-GFP-H6 nanocarrier targeting CXCR4.

Main Results:

• CXCR4 was overexpressed in 91% of human EC samples, identifying them as candidates for CXCR4-targeted therapies.
• Developed CXCR4+ EC mouse models demonstrated enhanced metastasis, particularly to the lungs and liver, with 100% penetrance.
• The CXCR4-targeted nanocarrier showed significant accumulation (60%) in subcutaneous tumors with no observed toxicity in normal organs.

Conclusions:

• CXCR4 is a promising therapeutic target for advanced and metastatic endometrial cancer.
• The developed CXCR4+ EC models are valuable tools for testing novel CXCR4-targeted drugs and nanomedicines.
• This approach offers a potential new therapeutic strategy for patients with advanced, high-risk, or recurrent EC lacking effective treatments.